Clinical Trials
Category Added in a WPeMatico Campaign
-
Effects of Experimental Intermittent Theta Burst Stimulation on Negative Symptoms of Schizophrenia: A Double-Blind Sham-Controlled Study
Background: Negative symptoms remain among the most debilitating and treatment-resistant features of schizophrenia. Repetitive transcranial magnetic stimulation, particularly intermittent theta burst stimulation (iTBS), is emerging as a promising intervention targeting these domains.
-
Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of MDD, a single dose of psilocybin was associated with rapid antidepressant effects, observed by day 2 and persisting for more than 3 months on secondary outcomes; psilocybin was generally well tolerated, but some individuals required additional support after dosing due to anxiety. These results suggest that…
-
Mobile Application-Based Self-Management and Chronic Disease Platform Program for Improved Transitional Care of Older Adults With Diabetes
CONCLUSIONS: The program has the potential to improve transitional care in older adults with diabetes, warranting further promotion.
-
Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Objective: This post hoc analysis assessed the benefit-risk of aripiprazole once-monthly 400 mg (AOM 400) as acute and long-term maintenance treatment for patients diagnosed with schizophrenia, based on number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH).
-
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters
BACKGROUNDThe relationship between molecular subgroups in clear-cell renal cell carcinoma (ccRCC) and metastatic tropism is poorly understood.METHODSWe analyzed over 5,000 metastatic sites from 305 treatment-naive ccRCC patients in the IMmotion150 phase II clinical trial, where patients were randomized to atezolizumab, atezolizumab/bevacizumab, or sunitinib.RESULTSAngiogenic tumors (clusters 1 and 2) had a higher rate of pancreatic (21%…
-
Safety, tolerability, and concordance with interferon-gamma release assays of a recombinant ESAT6-MPT64 skin test: a phase 1 randomized clinical trial
CONCLUSION: The recombinant EM skin test is safe, well-tolerated, and demonstrates preliminary diagnostic accuracy comparable to IGRAs. By successfully validating the translational utility of the MPT64 (RD2) antigen in a human cohort, this study provides a strong proof-of-concept for the EM skin test as a scalable, specific, and cost-effective immunodiagnostic tool.
-
Correction: Safety, tolerability, and concordance with interferon-gamma release assays of a recombinant ESAT6-MPT64 skin test: a phase 1 randomized clinical trial
[This corrects the article DOI: 10.3389/fimmu.2026.1780294.].
-
Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer
CONCLUSIONS: Morning ICI infusions confer a modest but clinically meaningful survival benefit that is absent in chemotherapy controls, supporting a causal chronotherapeutic effect. Scheduling ICIs before noon represents a low-cost, immediately actionable strategy warranting prospective confirmation.
-
Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial
BACKGROUND: Nacubactam (OP0595) is a newly developed diazabicyclooctane β-lactamase inhibitor used in combination with cefepime or aztreonam. We assessed the efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam versus imipenem-cilastatin in complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis.
-
What Have We Learned From the Idiopathic Intracranial Hypertension Treatment Trial the William F. Hoyt Lecture
CONCLUSIONS: Acetazolamide plus diet gave statistically significant improvements of visual function, papilledema, CSF pressure, and quality of life in patients with IIH with mild visual loss. A maximally tolerated dose up to 4 g/day is recommended.